Is Your Life Sciences Company Prepared for an FDA Inspection or DOJ Investigation?
For many life sciences companies, regulatory enforcement seems like something that happens to someone else—until an FDA investigator arrives, a subpoena is received, or a whistleblower complaint triggers an internal investigation.
Today’s enforcement environment is increasingly focused on corporate compliance, documentation, transparency, and executive accountability.
Organizations that prepare before regulators arrive are significantly better positioned to navigate inspections efficiently and reduce legal exposure.
FDA Inspections Are Becoming More Sophisticated
Modern FDA inspections extend well beyond manufacturing operations.
Investigators may evaluate:
- Quality Management Systems
- Complaint handling
- CAPA procedures
- Clinical documentation
- Promotional review
- Supplier oversight
- Training records
- Computer system validation
- AI governance
- Document control
Companies should assume investigators will evaluate whether written policies accurately reflect day-to-day operations.
DOJ Enforcement Often Begins Internally
Many Department of Justice investigations originate from:
- Employee complaints
- Former employees
- Competitor allegations
- Healthcare professionals
- Vendor reports
- Whistleblower actions
Organizations should maintain effective reporting mechanisms and thoroughly investigate credible concerns before they escalate.
Five Warning Signs Your Compliance Program Needs Attention
Policies Haven’t Been Updated
Compliance policies should evolve alongside changes in FDA expectations, technology, and business operations.
Training Is Inconsistent
Employees should receive documented training appropriate to their responsibilities.
Third-Party Oversight Is Limited
Companies remain responsible for many activities performed by vendors, consultants, distributors, and contract organizations.
Vendor oversight should include:
- Due diligence
- Written agreements
- Compliance expectations
- Periodic monitoring
Documentation Is Incomplete
Regulators frequently rely on documentation to evaluate compliance.
If an activity is not documented appropriately, investigators may question whether it occurred.
Leadership Is Not Engaged
An effective compliance program requires visible support from executive leadership.
Compliance should be integrated into strategic business decisions—not treated solely as a legal function.
Internal Investigations Should Be Structured
When concerns arise, organizations should promptly evaluate:
- Scope of potential issues
- Document preservation
- Interview strategy
- Root cause analysis
- Corrective actions
- Disclosure obligations
Independent legal oversight often strengthens privilege protections while promoting objective decision-making.
Compliance Is More Than Written Policies
Effective compliance programs typically include:
- Written standards
- Leadership oversight
- Employee education
- Reporting mechanisms
- Risk assessments
- Monitoring
- Auditing
- Corrective actions
Together, these elements help demonstrate an organization’s commitment to compliance.
The Cost of Waiting
Companies often delay compliance investments until enforcement actions occur.
Unfortunately, by then:
- Investigations become expensive.
- Business operations are disrupted.
- Investor confidence may decline.
- Transactions can be delayed.
- Reputational damage may occur.
Proactive compliance planning frequently costs substantially less than responding to government enforcement.
How Kendall PC Helps Clients Prepare
Kendall PC advises pharmaceutical, biotechnology, medical device, digital health, and healthcare organizations on proactive compliance strategies designed to withstand regulatory scrutiny.
Our services include:
- FDA inspection readiness assessments
- Corporate compliance program development
- Internal investigations
- AI governance
- Medical Affairs compliance
- Promotional review
- Sunshine/Open Payments compliance
- HIPAA and privacy
- Executive compliance counseling
- Healthcare fraud and abuse risk assessments
Preparation Creates Confidence
Regulators understand that no organization is perfect.
However, companies that maintain strong governance, accurate documentation, effective training, and engaged leadership are generally better positioned to navigate inspections and investigations successfully.
Building compliance before regulators arrive remains one of the smartest investments a life sciences company can make.
Contact Kendall PC to discuss how we can help your organization prepare for FDA inspections and DOJ investigations.
